Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,520.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $22.52, for a total value of $22,520.00. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at approximately $292,760. The trade was a 7.14 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.

Enliven Therapeutics Stock Performance

ELVN opened at $22.00 on Friday. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The business has a fifty day simple moving average of $22.82 and a 200-day simple moving average of $24.24.

Analysts Set New Price Targets

ELVN has been the subject of several analyst reports. BTIG Research started coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Robert W. Baird raised their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $38.25.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Charles Schwab Investment Management Inc. increased its stake in Enliven Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company’s stock worth $5,892,000 after purchasing an additional 6,611 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after buying an additional 1,275 shares during the period. SG Americas Securities LLC increased its stake in Enliven Therapeutics by 66.1% during the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock worth $374,000 after buying an additional 6,616 shares during the period. Lord Abbett & CO. LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter worth approximately $8,199,000. Finally, Franklin Resources Inc. purchased a new position in Enliven Therapeutics in the 3rd quarter valued at approximately $559,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.